Methylation in esophageal carcinogenesis.

Area of Science:

• Molecular Oncology
• Epigenetics
• Gastroenterology

Background:

• Esophageal cancer pathogenesis involves genetic alterations in proto-oncogenes and tumor suppressor genes.
• Epigenetic modifications, particularly CpG island hypermethylation, are increasingly recognized as significant factors in esophageal carcinogenesis.
• Promoter hypermethylation of tumor suppressor genes is frequently observed in esophageal carcinomas.

Purpose of the Study:

• To review current research on genes undergoing hypermethylation in human esophageal cancer and precancerous lesions.
• To explore the role of epigenetic alterations in esophageal cancer development.
• To discuss the potential of hypermethylated genes as biomarkers for esophageal cancer detection, prognosis, and therapeutic targets.

Main Methods:

• Literature review of studies investigating gene promoter hypermethylation in esophageal cancer.
• Analysis of current research on epigenetic modifications in esophageal carcinogenesis.
• Synthesis of findings related to hypermethylated genes in precancerous and cancerous esophageal tissues.

Main Results:

• Significant association between promoter hypermethylation of tumor suppressor genes and esophageal cancer.
• Evidence supporting the role of epigenetic dysregulation in the pathogenesis of esophageal tumors.
• Identification of specific hypermethylated genes implicated in esophageal cancer development.

Conclusions:

• Promoter hypermethylation of tumor suppressor genes is a key epigenetic event in esophageal cancer.
• Hypermethylated genes represent promising targets for novel diagnostic and therapeutic strategies in esophageal cancer.
• Further research into epigenetic biomarkers could improve patient outcomes for esophageal cancer.